Assessing undertreatment and overtreatment/misuse of ADHD medications in children and adolescents across continents: A systematic review and meta-analysis

Imagem de Miniatura
Arquivos
art_MASSUTI_Assessing_undertreatment_and_overtreatmentmisuse_of_ADHD_medications_in_2021.PDF (1.07 MB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
MASSUTI, Rafael
MOREIRA-MAIA, Carlos Renato
CAMPANI, Fausto
SONEGO, Marcio
AMARO, Julia
AKUTAGAVA-MARTINS, Glaucia Chiyoko
TESSARI, Luca
CORTESE, Samuele
ROHDE, Luis Augusto
Citação
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, v.128, p.64-73, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
A controversy exists on whether there is an over or underuse of medications for Attention-Deficit/Hyperactivity Disorder (ADHD). We conducted the first meta-analysis to estimate the rate of ADHD pharmacological treatment in both diagnosed and undiagnosed individuals. Based on a pre-registered protocol (CRD42018085233), we searched a broad set of electronic databases and grey literature. After screening 25,676 abstracts, we retained 36 studies including 104,305 subjects, from which 18 studies met our main analysis criteria. The pooled pharmacological treatment rates were 19.1 % and 0.9 % in school-age children/adolescents with and without ADHD, respectively. We estimated that for each individual using medication without a formal ADHD diagnosis, there are three patients with a formal diagnosis who might benefit from medication but do not receive it in the US. Our results indicate both overtreatment/misuse of medication in individuals without ADHD and pharmacological undertreatment in youths with the disorder. Our findings reinforce the need for public health policies improving education on ADHD and discussions on the benefits and limitations of ADHD medications.
Palavras-chave
ADHD, Prevalence, Treatment, Stimulants, Pharmacological interventions
URI
https://observatorio.fm.usp.br/handle/OPI/44561
Referências
  1. American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI 10.1176/appi.books.9780890425596
  2. Angold A, 2000, J AM ACAD CHILD PSY, V39, P975, DOI 10.1097/00004583-200008000-00009
  3. Barbaresi W, 2002, ARCH PEDIAT ADOL MED, V156, P217, DOI 10.1001/archpedi.156.3.217
  4. Bauermeister JJ, 2003, J AM ACAD CHILD PSY, V42, P851, DOI 10.1097/01.CHI.0000046864.56865.30
  5. Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1042, DOI [10.1097/01.chi.0000227879.65651.cf, 10.1097/01.chi.0000227878.58027.3d]
  6. Bolea-Alamanac B, 2014, J PSYCHOPHARMACOL, V28, P179, DOI 10.1177/0269881113519509
  7. Breggin P, 2011, NEW YORK TIMES
  8. Bussing R, 2005, J CHILD ADOL PSYCHOP, V15, P78, DOI 10.1089/cap.2005.15.78
  9. CADDRA, 2021, CAN ATT DEF HYP DIS
  10. Caye A, 2019, MOL PSYCHIATR, V24, P390, DOI 10.1038/s41380-018-0116-3
  11. Chang Z, 2017, JAMA PSYCHIAT, V74, P597, DOI 10.1001/jamapsychiatry.2017.0659
  12. Chang Z, 2016, BIOL PSYCHIAT, V80, P916, DOI 10.1016/j.biopsych.2016.02.018
  13. Cohen YG, 2015, J NEUROSCI RURAL PRA, V6, P320, DOI 10.4103/0976-3147.158749
  14. Coles EK, 2020, J CLIN CHILD ADOLESC, V49, P673, DOI 10.1080/15374416.2019.1630835
  15. Concannon PE, 2005, J PAEDIATR CHILD H, V41, P625, DOI 10.1111/j.1440-1754.2005.00771.x
  16. Cortese S, 2020, NEW ENGL J MED, V383, P1050, DOI 10.1056/NEJMra1917069
  17. Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4
  18. Dalsgaard S, 2015, LANCET PSYCHIAT, V2, P702, DOI 10.1016/S2215-0366(15)00271-0
  19. Dalsgaard S, 2015, LANCET, V385, P2190, DOI 10.1016/S0140-6736(14)61684-6
  20. Danielson ML, 2018, J CLIN CHILD ADOLESC, V47, P199, DOI 10.1080/15374416.2017.1417860
  21. Danielson ML, 2017, J DEV BEHAV PEDIATR, V38, P455, DOI 10.1097/DBP.0000000000000477
  22. de Graaf R, 2008, OCCUP ENVIRON MED, V65, P835, DOI 10.1136/oem.2007.038448
  23. de Leon J, 2014, J CLIN PSYCHOPHARM, V34, P545, DOI 10.1097/JCP.0000000000000126
  24. DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
  25. Doshi JA, 2012, J AM ACAD CHILD PSY, V51, P990, DOI 10.1016/j.jaac.2012.07.008
  26. Efron D, 2020, ARCH DIS CHILD, V105, P593, DOI 10.1136/archdischild-2019-317997
  27. Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
  28. Epstein-Ngo QM, 2016, J PEDIATR PSYCHOL, V41, P786, DOI 10.1093/jpepsy/jsv105
  29. Fairman RT, 2021, J AM COLL HEALTH, V69, P767, DOI 10.1080/07448481.2019.1706539
  30. Faraone SV, 2020, J AM ACAD CHILD PSY, V59, P100, DOI 10.1016/j.jaac.2019.06.012
  31. Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857
  32. Galera C, 2014, BRIT J PSYCHIAT, V205, P291, DOI 10.1192/bjp.bp.113.141952
  33. Gezondheidsraad, 2014, ADHD MED MAATSCH
  34. Greenhill L, 2006, J AM ACAD CHILD PSY, V45, P1284, DOI 10.1097/01.chi.0000235077.32661.61
  35. Gudmundsdottir BG, 2020, J ATTEN DISORD, V24, P384, DOI 10.1177/1087054716684379
  36. Hailpern SM, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00100
  37. Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
  38. Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P797, DOI 10.1097/00004583-199907000-00008
  39. Jones BE, 2017, ANN INTERN MED, V166, P844, DOI 10.7326/M17-1061
  40. Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617
  41. Kirova AM, 2019, PSYCHIAT RES, V274, P75, DOI 10.1016/j.psychres.2019.02.003
  42. Knopf H, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000477
  43. Lichtenstein P, 2012, NEW ENGL J MED, V367, P2006, DOI 10.1056/NEJMoa1203241
  44. Lin LF, 2018, J GEN INTERN MED, V33, P1260, DOI 10.1007/s11606-018-4425-7
  45. Luby JL, 2007, J CHILD ADOL PSYCHOP, V17, P205, DOI 10.1089/cap.2007.0023
  46. Merikangas KR, 2013, JAMA PEDIATR, V167, P141, DOI 10.1001/jamapediatrics.2013.431
  47. MILLER RG, 1974, BIOMETRIKA, V61, P1
  48. Montiel C, 2008, CHILD PSYCHIAT HUM D, V39, P311, DOI 10.1007/s10578-007-0090-5
  49. Moreira-Maia CR, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010923
  50. Mortier P, 2015, Tijdschr Psychiatr, V57, P635
  51. NICE, 2018, NICE GUID N G 87 ATT
  52. OConnell D., 2021, CLIN EPIDEMIOL
  53. Piper BJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206100
  54. Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724
  55. Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942
  56. Raman SR, 2018, LANCET PSYCHIAT, V5, P824, DOI 10.1016/S2215-0366(18)30293-1
  57. Reich W, 2006, J AM ACAD CHILD PSY, V45, P801, DOI 10.1097/01.chi.0000219833.00979.c3
  58. Renoux C, 2016, BRIT J CLIN PHARMACO, V82, P858, DOI 10.1111/bcp.13000
  59. Rieppi R, 2002, J AM ACAD CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006
  60. Ruiz-Goikoetxea M, 2018, NEUROSCI BIOBEHAV R, V84, P63, DOI 10.1016/j.neubiorev.2017.11.007
  61. Russell AE, 2019, SOC PSYCH PSYCH EPID, V54, P1555, DOI 10.1007/s00127-019-01720-y
  62. SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256
  63. Saul R, 2014, TIME MAGAZINE
  64. Sawyer MG, 2002, MED J AUSTRALIA, V177, P21, DOI 10.5694/j.1326-5377.2002.tb04624.x
  65. Sawyer MG, 2017, J CHILD ADOL PSYCHOP, V27, P177, DOI 10.1089/cap.2016.0017
  66. Sayal K, 2010, PSYCHIAT SERV, V61, P803, DOI 10.1176/ps.2010.61.8.803
  67. Schmitz M, 2006, J AM ACAD CHILD PSY, V45, P1338, DOI 10.1097/S0890-8567(09)61916-X
  68. Sciberras E, 2016, CHILD CARE HLTH DEV, V42, P709, DOI 10.1111/cch.12363
  69. Septier M, 2019, NEUROSCI BIOBEHAV R, V103, P109, DOI 10.1016/j.neubiorev.2019.05.022
  70. Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007]
  71. Simon V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827
  72. St Amour MD, 2018, CAN J PUBLIC HEALTH, V109, P395, DOI 10.17269/s41997-018-0067-0
  73. Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
  74. Sun SH, 2019, JAMA PSYCHIAT, V76, P1141, DOI 10.1001/jamapsychiatry.2019.1944
  75. SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P205, DOI 10.1111/j.1469-7610.1989.tb00235.x
  76. Szobot CM, 2007, ADDICTION, V102, P1122, DOI 10.1111/j.1360-0443.2007.01850.x
  77. Taylor E, 2004, EUR CHILD ADOLES PSY, V13, P7, DOI 10.1007/s00787-004-1002-x
  78. Taylor E, 2014, NORD J PSYCHIAT, V68, P236, DOI 10.3109/08039488.2013.804118
  79. Thomas R, 2015, PEDIATRICS, V135, pE994, DOI 10.1542/peds.2014-3482
  80. Tobi H, 2005, PHARMACOEPIDEM DR S, V14, P239, DOI 10.1002/pds.1081
  81. Toomey SL, 2011, ACAD PEDIATR, V11, P500, DOI 10.1016/j.acap.2011.08.010
  82. Tremmery S, 2007, EUR CHILD ADOLES PSY, V16, P327, DOI 10.1007/s00787-007-0604-5
  83. United Nations Department of Economic and Social Affairs Population Division, 2017, WORKING PAPER NO ESA
  84. Upadhyay N, 2017, SUBST USE MISUSE, V52, P1266, DOI 10.1080/10826084.2016.1273955
  85. Visser SN, 2007, PEDIATRICS, V119, pS99, DOI 10.1542/peds.2006-2089O
  86. Wallach-Kildemoes H, 2015, J DEV BEHAV PEDIATR, V36, P330, DOI 10.1097/DBP.0000000000000170
  87. Walls M, 2018, ACAD PEDIATR, V18, P256, DOI 10.1016/j.acap.2017.10.003
  88. Wang N., 2018, CONDUCT METAANALYSIS, DOI [10.13140/RG.2.2.27199.00161, DOI 10.13140/RG.2.2.27199.00161]
  89. Willcutt E, 2012, NEUROTHERAPEUTICS, V9, P490, DOI 10.1007/s13311-012-0135-8
  90. Wolraich ML, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-2528
  91. Yttri J. -E., 2017, UGESKRIFT LAEGER, V179
  92. Zablotsky B, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0811
  93. Zubrick, 2015, MENTAL HLTH CHILDREN
  94. Zuvekas SH, 2012, AM J PSYCHIAT, V169, P160, DOI 10.1176/appi.ajp.2011.11030387

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/23